S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis
Open Access
- 8 July 2021
- journal article
- research article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 11 (7), e459
- https://doi.org/10.1002/ctm2.459
Abstract
Dysregulated expression of S100A7 is found in several cancers and plays an important role in tumor progression; however, its carcinogenic role in esophageal squamous carcinoma (ESCC) is still poorly understood. Here, we identified that the levels of S100A7 were remarkably upregulated in 341 tumor tissues (P < .001) and 274 serum samples (P < .001) of ESCC patients compared with normal control. It was an independent prognostic factor (P = .026). Furthermore, a new diagnostic model for ESCC based on serum S100A7, SCC, and crfra21-1 was established with area under curve (AUC) up to 0.863 (95% CI: 0.802-0.925). Mechanically, we found upregulated S100A7 could promote cell migration and proliferation through intracellular binding to JAB1 and paracrine interaction with RAGE receptors and then activates the downstream signaling pathways. In addition, exocrine S100A7 could promote M2 macrophage infiltration and polarization by up-regulating M2 macrophage associated proteins, and tumor angiogenesis by enhancing the activation of p-ErK and p-FAK pathways. Further animal experiments confirmed the role of S100A7 in promoting M2 macrophage infiltration and angiogenesis in ESCC. In conclusion, these findings highlighted the potential diagnostic and prognostic value of S100A7 in patients with ESCC. Meanwhile, our results reveal that S100A7 promotes tumor progression by activating oncogenic pathways and remodeling tumor microenvironment, which paving the way for the progress of S100A7 as a therapeutic target for cancer treatment.Keywords
Funding Information
- Natural Science Foundation of Beijing Municipality (7204291)
This publication has 45 references indexed in Scilit:
- The clinical significance of Psoriasin for non-small cell lung cancer patients and its biological impact on lung cancer cell functionsBMC Cancer, 2012
- S100A7 promotes the migration and invasion of osteosarcoma cells via the receptor for advanced glycation end productsOncology Letters, 2012
- S100A7 Enhances Mammary Tumorigenesis through Upregulation of Inflammatory PathwaysCancer Research, 2012
- Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferationBreast Cancer Research and Treatment, 2011
- Global Gene Expression Profiling and Validation in Esophageal Squamous Cell Carcinoma and Its Association with Clinical PhenotypesClinical Cancer Research, 2011
- RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and InflammationJournal of Translational Medicine, 2009
- Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumoursZeitschrift für Krebsforschung und Klinische Onkologie, 2006
- The S100A7-c-Jun Activation Domain Binding Protein 1 Pathway Enhances Prosurvival Pathways in Breast CancerCancer Research, 2005
- Differential expression of S100 gene family in human esophageal squamous cell carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2004
- Amino Acid Sequence Analysis of Human S100A7 (Psoriasin) by Tandem Mass SpectrometryBiochemical and Biophysical Research Communications, 1995